https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=Clemente+Perea%5Bauthor%5D&datetype=edat&usehistory=y&retmax=1&tool=pubfacts&email=info@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&WebEnv=MCID_679579ca80a6f163aa0bcc6d&query_key=1&retmode=xml&retstart=-10&retmax=25&tool=pubfacts&email=info@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908
Background: The use of microarray technology has resulted in a new classification of breast cancer according to gene expression profiles. None of the reports published so far using this new classification has stratified the studied tumors by histology or size.
Materials And Methods: This study was restricted to the ductal infiltrating variety only, and to pT1 size using the immunohistochemical markers estrogen receptor (ER), progesterone receptor (PR), HER2 and cytokeratin 5/6.